Effectiveness of Anti-tumor Necrosis Factor Drugs on Hidradenitis Suppurativa
Author Information
Author(s): Muacevic Alexander, Adler John R, Samifanni Rojina, Gatt Vincent, Kabore Jessica, Silva Mariangela, Khan Manal, Kollias Theofanis F, Clunes Lucy A
Primary Institution: St. George's University School of Medicine
Hypothesis
Are anti-TNF drugs effective in treating hidradenitis suppurativa?
Conclusion
Anti-TNF drugs, particularly adalimumab, show significant effectiveness in treating hidradenitis suppurativa, but high relapse rates after treatment discontinuation remain a challenge.
Supporting Evidence
- Adalimumab has shown a clinical response rate of around 60-70%.
- High relapse rates following treatment discontinuation remain a challenge.
- Emerging treatments like anti-IL-17 agents show promise with response rates up to 82%.
- Combination therapies may provide better symptom control and reduce relapse.
Takeaway
This study looks at how well certain medicines work for a painful skin condition called hidradenitis suppurativa. It finds that some treatments help a lot, but people often have problems again after stopping the medicine.
Methodology
The review analyzed 13 publications from 2010 to 2023 focusing on the effectiveness of anti-TNF drugs for HS.
Potential Biases
Moderate bias rating based on the GRADE scale.
Limitations
The review is limited by the variability in patient responses and the high relapse rates after treatment discontinuation.
Participant Demographics
The studies included both men and women, with a higher proportion of affected women reported.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website